Dr. Young on Other Options for Managing Bleeding in Children With Cancer

Guy Young, MD
Published: Monday, Oct 23, 2017



Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses other options for managing bleeding in children with cancer.

For hospitalized children with cancer who develop a blood clot, bivalirudin (Angiomax), an intravenous-direct thrombin inhibitor, can be better than the traditionally-used heparin therapy, says Young.
 


Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses other options for managing bleeding in children with cancer.

For hospitalized children with cancer who develop a blood clot, bivalirudin (Angiomax), an intravenous-direct thrombin inhibitor, can be better than the traditionally-used heparin therapy, says Young.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Management of Adverse Events Associated with Therapies for Hematological Disorders: Nurses' PerspectiveApr 21, 20182.0
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Publication Bottom Border
Border Publication
x